加拿大糖尿病护理药物和设备市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按药物(按类别(胰岛素、口服抗糖尿病药物、非胰岛素注射药物和组合药物)、子细分(基础或长效、丸剂或速效、传统人胰岛素药物)细分、胰岛素生物仿制药、GLP-1 受体激动剂、α-葡萄糖苷酶抑制剂、DPP-4 抑制剂和 SGLT-2 抑制剂)和设备(管理设备(胰岛素泵、胰岛素笔、注射器、药筒和喷射注射器)和监测设备(自我监测血糖(医院和个人使用)和连续血糖监测)。

市场快照

Canada diabetes care Drugs and Devices market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: >5 %
Canada diabetes care Drugs and Devices market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

预计加拿大糖尿病护理药物和设备市场在预测期间(2019-2025 年)的复合年增长率将超过 5.3%。

  • 由于糖尿病患病率的上升和该国设备用户数量的增加,预计监测设备将在预测期内主导市场。
  • 从胰岛素注射到胰岛素泵,胰岛素输送系统技术有了显着增长。
  • 加拿大糖尿病护理设备市场,监测设备在 2019 年占据最高的市场份额,为 11.28%。自我监测血糖设备占据市场份额最高,试纸量最大。

报告范围

市场按药物(按类别(胰岛素、口服抗糖尿病药物、非胰岛素注射药物和组合药物)、子细分(基础或长效、丸剂或速效、传统人胰岛素药物)细分、胰岛素生物仿制药、GLP-1 受体激动剂、α-葡萄糖苷酶抑制剂、DPP-4 抑制剂和 SGLT-2 抑制剂)和设备(管理设备(胰岛素泵、胰岛素笔、注射器、药筒和喷射注射器)和监测设备(自我监测血糖和连续血糖监测))。

By Drug
Oral anti-diabetic drugs
Biguanide (Value and Volume 2012-2025)
Metformin
Alpha - Glucosidase inhibitors (Value and Volume 2012-2025)
Alpha - Glucosidase inhibitors
Dopamine -D2 receptor agonist (Value and Volume 2012-2025)
Bromocriptin( Cycloset)
Sodium - glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2025)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Value and Volume 2012-2025)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2025)
Sulfonylureas
Meglitinide (Value and Volume 2012-2025)
Meglitinide
Insulin (Value and Volume 2012-2025)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin Aspart)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Combination Insulins (Value and Volume 2012-2025)
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
Oral Combination (Value and Volume 2012-2025)
Janumet (Sitagliptin and Metformin HCl)
Non-Insulin Injectable drugs (Value and Volume 2012-2025)
GLP1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue (Value and Volume 2012-2025)
Symlin (Pramlintide)
By Devices
By Monitoring Devices (Value, and Volume, 2012-2025)
Self-Monitoring Blood Glucose
Glucometer Devices
Blood Glucose Test Strips
Lancets
Continuous Glucose Monitoring (Value, and Volume, 2012-2025)
Sensors
Durables
By Management Devices (Value, and Volume, 2012-2025)
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Cartridges in Reusable pens
Insulin Disposable Pens
Jet Injectors

Report scope can be customized per your requirements. Click here.

主要市场趋势

2019年磺脲类和二甲双胍占据加拿大口服糖尿病药物市场67%的份额

2019年,二甲双胍在加拿大糖尿病药物和器械市场占有28.64%的市场份额。当饮食不足以提供健康的生活方式时,二甲双胍已被证明是治疗糖尿病的有效药物。与其他刺激胰岛素释放的药物相比,二甲双胍增加了身体对胰岛素的敏感性,从而有助于降低患者的血糖水平。由于二甲双胍市场上有许多仿制药厂商,亚太地区的市场份额最高。磺脲类药物在加拿大口服糖尿病药物市场占有率最高,第二代磺脲类药物副作用较少,包括格列吡嗪(Glucotrol)、格列本脲(Micronase、Glynase PresTabs和DiaBeta),以及最新的药物格列美脲(Amaryl)。单剂,

Canada diabetes care Drugs and Devices market Key Trends

监测设备在加拿大糖尿病设备市场中的市场份额最高

在加拿大糖尿病监测设备中,监测设备在 2019 年占据了 48.7% 的市场份额。由于与血糖仪相关的意识不断提高和成本降低,预计个人使用的血糖仪未来将出现高销量。由于有利的医疗保险政策,预计在预测期内,所研究市场的血糖仪部分将出现高增长。加拿大监测设备市场的增长是由于连续血糖监测设备 (CGM) 使用量的增加。2019 年,DexCom Inc. 为加拿大两岁及以上的糖尿病患者推出了 Dexcom G6 CGM 系统。

Canada diabetes care Drugs and Devices market Growth by Region

竞争格局

制造商不断创新以在市场上竞争。雅培和美敦力等主要参与者经历了多次并购和合作,以建立市场主导地位,同时也坚持有机增长战略,这从这些公司的研发支出中可以看出。胰岛素输送设备的制造商在设备的研发上投入了大量资金。例如,诺和诺德与雅培糖尿病护理公司合作,这可能有助于在诺和诺德连接的胰岛素笔和与 FreeStyle Libre 产品组合兼容的数字健康工具之间共享胰岛素数据。赛诺菲制造的 Mega Blockbuster Lantus 引领基​​础胰岛素领域。来得时全球销售额在 2014 年达到顶峰时超过 70 亿美元。2019 年,

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Drivers

    2. 4.2 Market Restraints

  5. 5. Market Segmentation

    1. 5.1 By Drug

      1. 5.1.1 Oral anti-diabetic drugs

        1. 5.1.1.1 Biguanide (Value and Volume 2012-2025)

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha - Glucosidase inhibitors (Value and Volume 2012-2025)

          1. 5.1.1.2.1 Alpha - Glucosidase inhibitors

        3. 5.1.1.3 Dopamine -D2 receptor agonist (Value and Volume 2012-2025)

          1. 5.1.1.3.1 Bromocriptin( Cycloset)

        4. 5.1.1.4 Sodium - glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2025)

          1. 5.1.1.4.1 Invokana (Canagliflozin)

          2. 5.1.1.4.2 Jardiance (Empagliflozin)

          3. 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.4.4 Suglat (Ipragliflozin)

        5. 5.1.1.5 Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Value and Volume 2012-2025)

          1. 5.1.1.5.1 Januvia (Sitagliptin)

          2. 5.1.1.5.2 Onglyza (Saxagliptin)

          3. 5.1.1.5.3 Tradjenta (Linagliptin)

          4. 5.1.1.5.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.5.5 Galvus (Vildagliptin)

        6. 5.1.1.6 Sulfonylureas (Value and Volume 2012-2025)

          1. 5.1.1.6.1 Sulfonylureas

        7. 5.1.1.7 Meglitinide (Value and Volume 2012-2025)

          1. 5.1.1.7.1 Meglitinide

      2. 5.1.2 Insulin (Value and Volume 2012-2025)

        1. 5.1.2.1 Basal or Long Acting Insulins

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast Acting Insulins

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

          4. 5.1.2.2.4 FIASP (Insulin Aspart)

        3. 5.1.2.3 Traditional Human Insulins

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humilin

      3. 5.1.3 Combination Insulins (Value and Volume 2012-2025)

        1. 5.1.3.1 NovoMix (Biphasic Insulin Aspart)

        2. 5.1.3.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 5.1.3.3 Xultophy (Insulin Degludec and Liraglutide)

        4. 5.1.3.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)

      4. 5.1.4 Oral Combination (Value and Volume 2012-2025)

        1. 5.1.4.1 Janumet (Sitagliptin and Metformin HCl)

      5. 5.1.5 Non-Insulin Injectable drugs (Value and Volume 2012-2025)

        1. 5.1.5.1 GLP1 receptor agonists

          1. 5.1.5.1.1 Victoza (Liraglutide)

          2. 5.1.5.1.2 Byetta (Exenatide)

          3. 5.1.5.1.3 Bydureon (Exenatide)

          4. 5.1.5.1.4 Trulicity (Dulaglutide)

          5. 5.1.5.1.5 Lyxumia (Lixisenatide)

        2. 5.1.5.2 Amylin Analogue (Value and Volume 2012-2025)

          1. 5.1.5.2.1 Symlin (Pramlintide)

    2. 5.2 By Devices

      1. 5.2.1 By Monitoring Devices (Value, and Volume, 2012-2025)

        1. 5.2.1.1 Self-Monitoring Blood Glucose

          1. 5.2.1.1.1 Glucometer Devices

          2. 5.2.1.1.2 Blood Glucose Test Strips

          3. 5.2.1.1.3 Lancets

        2. 5.2.1.2 Continuous Glucose Monitoring (Value, and Volume, 2012-2025)

          1. 5.2.1.2.1 Sensors

          2. 5.2.1.2.2 Durables

      2. 5.2.2 By Management Devices (Value, and Volume, 2012-2025)

        1. 5.2.2.1 Insulin Pump

          1. 5.2.2.1.1 Insulin Pump Device

          2. 5.2.2.1.2 Insulin Pump Reservoir

          3. 5.2.2.1.3 Infusion Set

        2. 5.2.2.2 Insulin Syringes

        3. 5.2.2.3 Cartridges in Reusable pens

        4. 5.2.2.4 Insulin Disposable Pens

        5. 5.2.2.5 Jet Injectors

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population (2012-2025)

    2. 6.2 Type-2 Diabetic Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk A/S

      2. 7.1.2 Sanofi Aventis

      3. 7.1.3 Eli Lilly

      4. 7.1.4 AstraZeneca

      5. 7.1.5 AstraZeneca

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Bristol Myers Squibb

      8. 7.1.8 Roche

      9. 7.1.9 Abbott

      10. 7.1.10 Johnson and Johnson (Lifescan)

      11. 7.1.11 Arkray

      12. 7.1.12 Ascensia Diabetes Care

      13. 7.1.13 AgaMatrix Inc.

      14. 7.1.14 Dexcom

      15. 7.1.15 Medtronic

      16. 7.1.16 Becton Dickinson

      17. 7.1.17 Ypsomed Holding AG

      18. 7.1.18 Ypsomed Holding AG

      19. 7.1.19 Terumo

      20. 7.1.20 LMC Diabetes and Endocrinology

      21. 7.1.21 Bayshore Health Care

      22. 7.1.22 Express Scripts

      23. 7.1.23 One Drop

      24. 7.1.24 Telus Health

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Canada Diabetes Care Drugs and Devices Market market is studied from 2016 - 2027.

The Canada Diabetes Care Drugs and Devices Market is growing at a CAGR of >5% over the next 5 years.

Roche, Medtrionic, Sanofi, Novo Nordisk, Omnipod are the major companies operating in Canada Diabetes Care Drugs and Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!